Back to search results

Study of EGFR FPBMC for Metastatic or Unresectable Pancreatic Cancer

This study is looking at a new treatment called EGFR FPBMC for people with pancreatic cancer that has spread (metastatic) or cannot be removed by surgery (unresectable). You might be able to join if you've already had at least one type of chemotherapy and your cancer has been stable for at least three months. The main goal is to see how safe EGFR FPBMC is, especially looking for any serious side effects during the first eight infusions. Researchers also want to get an idea of how well it works. EGFR FPBMC is a type of immunotherapy that uses your own white blood cells, specifically T cells, to target and kill cancer cells that have a marker called EGFR. The study plans to enroll 23 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 23 participants, but the phase of the study is not specified.
What's involved
You would have a procedure called leukapheresis to collect your white blood cells. Then, you would receive 8 infusions of EGFR FPBMC twice a week, followed by another leukapheresis and 8 more infusions every two weeks. Blood samples will be collected before, during, and after treatment, and your disease status will be checked regularly.
Compensation
Not stated in the trial record.
Follow-up
Disease status will be checked regularly during and after study treatment. Dose-limiting toxicities will be measured about 4 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06479239

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
University of Virginia
~23 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:EGFR FPBMC

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose limiting toxicities (DLTs) during the dose escalation phase (during the first 8 infusions only)
Measured over Through the dose escalation phase (during the first 8 infusions only, about 4 weeks after starting study treatment))

Conditions

Pancreas Cancer
Pancreatic Cancer

Explore related trials

Pancreatic CarcinomaSoluble Epidermal Growth Factor Receptor

Where it's being run

1 sites across 1 states
Virginia1

Study leadership

  • Tri Le, MD, DSc · PRINCIPAL_INVESTIGATOR · University of Virginia

Who to contact

Ashley Donihee
[email protected]
434-243-6377
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Absolute neutrophil count \>= 500/mm3
Absolute lymphocyte count \>= 400/mm3
Platelets \>= 75,000/mm3
Hemoglobin \>= 8 g/dL
Serum creatinine \< 2.0mg/dL or calculated/measured creatinine clearance \>= 50 ml/min
Bilirubin \<= 2 mg/dL
Aspartate transferase (AST) and Alanine transaminase (ALT) \<= 5.0 x upper limit of normal (ULN)
Alpha gal \< 0.35 IU/ml or "negative" 9. Ability to provide informed consent and provision of written informed consent 10. Stated willingness to comply with all study procedures and availability for the duration of the study 11. Adequate cardiac function as defined as:
No uncontrolled angina or severe ventricular arrhythmias
No clinically significant pericardial disease
No history of myocardial infarction (MI) in the last year before registration
No Class 3 or higher New York Heart Association Congestive Heart Failure

What this trial measures

  • Dose limiting toxicities (DLTs) during the dose escalation phase (during the first 8 infusions only)Through the dose escalation phase (during the first 8 infusions only, about 4 weeks after starting study treatment))

    As defined in the protocol